Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.70 |
| ▸ | NPC1 | O15118 | 10/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.70 |
| ▸ | PKM | P14618 | 4/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.70 |
| ▸ | RELA | Q04206 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | HTT | P42858 | 5/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4111928 | 0.85 | MAPT (0.68) | RAB9ANPC1SMN1; SMN2KMT2AHTT | |
| SCHEMBL4118526 | 0.84 | MAPT (0.66) | RAB9ANPC1SMN1; SMN2KMT2AHTT | |
| SCHEMBL4119167 | 0.84 | KMT2A (0.63) | RAB9ANPC1SMN1; SMN2PKMNFKB1 | |
| SCHEMBL4106282 | 0.84 | MAPT (0.61) | RAB9ANPC1SMN1; SMN2PKMNFKB1 | |
| SCHEMBL4118510 | 0.84 | KMT2A (0.72) | RAB9ANPC1SMN1; SMN2PKMNFKB1 | |
| SCHEMBL4115554 | 0.82 | MEN1 (0.59) | RAB9ANPC1SMN1; SMN2KMT2AHTT | |
| SCHEMBL4124838 | 0.81 | IDO1 (0.58) | RAB9ANPC1SMN1; SMN2PKMNFKB1 | |
| SCHEMBL4124133 | 0.81 | MAPT (0.59) | SMN1; SMN2KMT2AHTTMAPTMEN1 | |
| SCHEMBL4116853 | 0.81 | MAPT (0.62) | RAB9ASMN1; SMN2PKMKMT2AHTT | |
| SCHEMBL4115667 | 0.80 | KMT2A (0.60) | RAB9ANPC1SMN1; SMN2KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | RAB9A 815/4885NPC1 927/4885SMN1; SMN2 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.